BioCentury
ARTICLE | Clinical News

Controlled release nitazoxanide: Phase II data

February 23, 2009 8:00 AM UTC

Data from the double-blind, placebo-controlled Phase III OPTIMA HCN-2 trial in 41 treatment-naïve patients with chronic HCV genotype 4 showed that twice-daily 675 and 1,350 mg controlled release nitaz...